Previously, A2AR antagonist-D2R agonist bivalent compounds were proposed as tools to find A2AR-D2R receptor heteromers and as a novel strategy for treatment of Parkinson's disease [84]. This evidence concerns the gene ADORA2A and Parkinson disease.